JOVANA
Library Glossary Getting Started Three Levels Fields How it works Mission
Join the mission
All guides

Bioequivalence & Generic Substitution

When can a pharmacist swap the brand for a generic? Bioequivalence is the legal and scientific answer — built on AUC and Cmax confidence intervals, the 80–125% rule, and the difference between pharmaceutical and therapeutic equivalence.

Same drug is not enough

A generic product contains the same active ingredient, in the same strength and dosage form, as the brand it copies. That sameness is called pharmaceutical equivalence — but it is only a statement about composition, not about what the body experiences. Two pharmaceutically equivalent products could still release the drug at different rates and deliver different blood levels. To allow a pharmacist to substitute one for the other, we need proof that the body cannot tell them apart. That proof is bioequivalence.

The 80–125% rule

Bioequivalence is decided by a crossover study: healthy volunteers take the test product on one occasion and the reference on another, and we compare their AUC (extent) and Cmax (rate). We do not demand that the averages be identical — that is impossible with biological variability. Instead we compute the 90% confidence interval for the ratio of test to reference, and require that this entire interval falls between 80% and 125%. If it does, the products are bioequivalent.

The 80–125% range looks asymmetric, but it is symmetric on a logarithmic scale — 0.80 and 1.25 are reciprocals (1 ÷ 0.8 = 1.25). That is why AUC and Cmax are analysed after a log transformation. The point is honest: a generic is not claimed to be molecularly identical in performance, only close enough that the difference is clinically meaningless. This is really a statement about relative bioavailability held to a tight, pre-agreed tolerance.

Bioequivalence verdict (log-transformed AUC and Cmax)

Test/Reference geometric mean ratio and 90% CI:

  AUC ratio  = 1.04   90% CI [0.96, 1.12]   -> inside 0.80-1.25  PASS
  Cmax ratio = 1.11   90% CI [0.98, 1.26]   -> upper bound 1.26 > 1.25  FAIL

Verdict: NOT bioequivalent (Cmax interval exceeds the limit).

Note: the whole 90% CI must lie within 0.80-1.25, not just the point estimate.
      0.80 and 1.25 are reciprocals (1/0.80 = 1.25) -> symmetric in log space.
Both AUC and Cmax intervals must sit entirely within 80–125%; one failure sinks the claim.

When a study can be waived

Human studies are expensive and expose volunteers to drug for no therapeutic benefit. For low-risk cases, regulators allow a biowaiver: bioequivalence is accepted on in-vitro evidence alone. This is most often granted to immediate-release products of BCS Class I and Class III drugs — the ones whose absorption is not limited by dissolution — provided the product dissolves rapidly and the excipients do not affect absorption. The class you established back in guide two literally decides whether a clinical study is needed.